The use of i.v. IG therapy in dermatology

Dermatologic Therapy

Volumn 20, Issue 4, 2007, Pages 288-305

  Fernandez, Anthony P ^a   Kerdel, Francisco A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Cedars Medical Center Miami   (United States)

Author keywords

Autoimmune mucocutaneous bullous diseases; Dermatomyositis; Intravenous human immunoglobulin (i.v. IG); Toxic epidermal necrolysis; Vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; DAPSONE; DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB; VACCINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ALOPECIA; ANAPHYLAXIS; ASEPTIC MENINGITIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BACKACHE; BLOOD CLOTTING; BLOOD VISCOSITY; BRONCHOSPASM; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; CHILL; CONNECTIVE TISSUE DISEASE; CYTOPENIA; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; ECZEMA; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEMOLYSIS; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION; KIDNEY DISEASE; LICHENOID; LUNG EDEMA; LUNG EMBOLISM; LUNG INJURY; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; NAUSEA; NEPHROSIS; OSTEOPOROSIS; PEMPHIGOID GESTATIONIS; PEMPHIGUS VULGARIS; PETECHIA; POLYMYOSITIS; PRURITUS; RESPIRATORY DISTRESS; REVIEW; RHINITIS; RISK FACTOR; SCLEROMYXEDEMA; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STROKE; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC SHOCK SYNDROME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URTICARIA; VASCULAR DISEASE; VASCULITIS; VOMITING; WHEEZING;

ANIMALS; AUTOIMMUNE DISEASES; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SKIN DISEASES; VASCULITIS;

EID: 35648948437     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00142.x     Document Type: Review

References (279)

1. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 117 (4 Suppl S525 S553. Erratum in: J Allergy Clin Immunol 2006: 117 (6): 1483. dosage error in text.
2. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006 : 6 : 592 599.
3. Martin TD. IGIV: contents, properties, and methods of industrial production - evolving closer to a more physiologic product. Int Immunopharmacol 2006 : 6 : 517 522.
4. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006 : 6 : 528 534.
5. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003 : 3 : 1325 1333.
6. Letko E, Bhol K, Foster SC, Ahmed RA. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr Eye Res 2000 : 21 : 646 654.
7. Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 2002 : 129 : 533 540.
8. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003 : 17 : 641 645.
9. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003 : 13 : 377 381.
10. Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 2002 : 105 : 192 198.
11. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v. Ig). Immunol Rev 1994 : 139 : 79 107.
12. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989 : 143 : 4104 4109.
13. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992 : 326 : 107 116.
14. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 : 139 : 1051 1059.
15. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999 : 340 : 227 228.
16. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of i.v.Ig. J Autoimmun 1993 : 6 : 683 689.
17. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, i.v.Ig). Ther Immunol 1994 : 1 : 269 277.
18. Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994 : 2 : 337 341.
19. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 : 291 : 484 486.
20. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003 : 111 : 697 703.
21. Basta M, Fries LF, Frank MM. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood 1991 : 78 : 700 702.
22. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994 : 139 : 21 42.
23. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993 : 79 : 211 216.
24. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994 : 14 : 178 189.
25. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994 : 73 : 180 186.
26. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994 : 139 : 5 19.
27. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995 : 95 : 1974 1978.
28. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 : 282 : 490 493.
29. Bayry J, Lacroix-Desmazes S, Delignat S, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003 : 48 : 3497 3502.
30. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003 : 101 : 758 765.
31. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 : 345 : 747 755.
32. Oravec S, Ronda N, Carayon A, Milliez J, Kazatchkine MD, Hornych A. Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro. Nephrol Dial Transplant 1995 : 10 : 796 800.
33. Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin. (Part 1 of 2). J Am Acad Derm 2007 : 56 : e1 e54.
34. Dalakas MC. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 1995 : 15 (6 Suppl 70S 75S.
35. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994 : 21 : 1092 1097.
36. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 : 329 : 1993 2000.
37. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991 : 91 : 162 168.
38. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998 : 65 : 107 110.
39. De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S. High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 1996 : 14 (Suppl. 15 S85 S92.
40. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002 : 61 : 37 41.
41. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995 : 72 : 25 28.
42. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991 : 91 : 169 172.
43. Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (i.v.IG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000 : 10 : 29 35.
44. Tsai MJ, Lai CC, Lin SC, Chiang BL, Chou CC, Hsieh KH. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Acta Paediatr 1997 : 38 : 111 115.
45. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol Suppl 1992 : 33 : 94 97.
46. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000 : 27 : 2498 2503.
47. Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002 : 29 : 75 83.
48. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994 : 12 : 163 168.
49. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High-dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996 : 23 : 71 75.
50. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999 : 8 : 705 712.
51. Silvestris F, D'Amore O, Cafforio P, Savino L, Dammaco F. Intravenous immune globulin therapy of lupus nephritis: use of pathogenicanti-DNA-reactive IgG. Clin Exp Immunol 1996 : 104 (Suppl. 1 91 97.
52. Lesprit P, Mouloud F, Bierling P, et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand J Rheumatol 1996 : 25 : 177 179.
53. Aharon A, Levy Y, Bar-Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with i.v.IG. Lupus 1997 : 6 : 408 411.
54. Aharon A, Zandman-Goddard G, Shoenfeld Y. Autoimmune multiorgan involvement in elderly men is it SLE? Clin Rheumatol 1994 : 13 : 631 634.
55. Meissner M, Sherer Y, Levy Y, Chwalinska-Sadowska H, Langevitz P, Shoenfeld Y. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000 : 19 : 199 201.
56. Levy Y, Sherer Y, George J, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999 : 119 : 231 238.
57. Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004 : 15 : 46 50.
58. Genereau T, Chosidow O, Danel C, Cherin P, Herson S. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999 : 135 : 1124 1125.
59. Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005 : 85 : 545 547.
60. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004 : 50 : 1005 1007.
61. Amital H, Rewald E, Levy Y, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003 February : 62 : 175 177.
62. Ulmer A, Kotter I, Pfaff A, Fierlbeck G. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol 2002 : 46 : 123 127.
63. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005 : 80 : 41 47.
64. Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1995 : 95 : 771 774.
65. DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol 2006 May : 54 : 855 865.
66. de la Torre Morin F, Garcia Robaina JC, Bonnet Moreno C, Fonta GL. Hyper-IgE syndrome. Presentation of three cases. Allergol Immunopathol (Madr) 1997 : 25 : 30 35.
67. Mahdi OZ, Mathelier LL, Al-Bardeisi NH. Hyperimmunoglobulin-E syndrome. Saudi Med J 2002 : 23 : 461 463.
68. Waldfahrer F, Pahl S, Federspil PA, Iro H. [Hyper-IgE syndrome with ENT manifestations. Overview and case report of successful therapy with high dosage i.v. immunoglobulin] HNO 1999 : 47 : 1063 1068.
69. Bilora F, Petrobelli F, Boccioletti V, Pomerri F. Moderate-dose intravenous immunoglobulin treatment of Job's syndrome. Case report. Minerva Med 2000 : 91 : 113 116.
70. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 : 139 : 1051 1059.
71. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002 : 138 : 385 389.
72. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998 : 16 : 235 251.
73. Mutasim DF, Anhalt GJ. Bullous diseases in the elderly. Clin Geriatr Med 2002 : 18 : 43 58.
74. Fontaine J, Joly P, Roujeau JC. Treatment of bullous pemphigoid. J Dermatol 2003 : 30 : 83 90.
75. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a U.S. medical center. J Invest Dermatol 2004 : 122 : 1091 1095.
76. Swerlick RA, Korman NJ. Bullous pemphigoid: what is the prognosis? J Invest Dermatol 2004 : 122 : XVII XVIII.
77. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 : 45 : 825 835.
78. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BPAg1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003 : 17 : 641 645.
79. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999 : 140 : 865 874.
80. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995 : 133 : 289 293.
81. Godard W, Roujeau JC, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985 : 103 : 964 965.
82. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979 : 101 : 521 534.
83. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006 : 6 : 557 578.
84. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000 : 42 : 422 427.
85. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol 1982 : 7 : 221 228.
86. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 : 45 : 679 690.
87. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003 : 13 : 377 381.
88. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002 : 138 : 1158 1162.
89. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002 : 47 : 358 363.
90. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996 : 135 : 128 129.
91. Colonna L, Cianchini G, Frezzolini A, De Pita O, Di Lella G, Puddu P. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy? Br J Dermatol 1998 : 138 : 1102 1103.
92. Sibaud V, Beylot-Barry M, Doutre MS, Beylot C. [Successful treatment of corticoid-resistant pemphigus with high-dose intravenous immunoglobulins]. [Article in French] Ann Dermatol Venereol 2000 : 127 : 408 410.
93. Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996 : 135 : 862 863.
94. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gamma-globulin in pemphigus. J Am Acad Dermatol 1990 : 22 (2 Part 1 326.
95. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989 : 20 : 684 685.
96. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995 : 133 : 1014 1016.
97. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006 : 355 : 1772 1779.
98. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 2002 : 12 : 174 178.
99. Sami N, Bhol KC, Ahmed AR. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses. Clin Exp Immunol 2001 : 125 : 492 498.
100. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002 : 46 : 42 49.
101. Toth GG, Jonkman MF. Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins. Br J Dermatol 1999 : 141 : 583 585.
102. Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 2002 : 105 : 192 198.
103. Person JR, Rogers RS 3rd. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977 : 113 : 610 615.
104. Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986 : 25 : 90 96.
105. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002 : 102 : 59 67.
106. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004 : 111 : 1380 1382.
107. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004 : 111 : 303 310.
108. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001 : 137 : 1181 1189.
109. Kumari S, Bhol KC, Rehman F, Foster CS, Ahmed AR. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine 2001 : 14 : 218 224.
110. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999 : 106 : 2136 2143.
111. Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol 2004 : 112 : 268 272.
112. Leverkus M, Georgi M, Nie Z, Hashimoto T, Brocker EB, Zillikens D. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol 2002 : 46 : 116 122.
113. Urcelay ML, McQueen A, Douglas WS. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997 : 137 : 477 478.
114. Engineer L, Dow EC, Braverman IM, Ahmed AR. Epidermolysis bullosa acquisita and multiple myeloma. J Am Acad Dermatol 2002 : 47 : 943 946.
115. Gourgiotou K, Exadaktylou D, Aroni K, et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2002 : 16 : 77 80.
116. Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol 2000 : 142 : 517 520.
117. Harman KE, Whittam LR, Wakelin SH, Black MM. Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol 1998 : 139 : 1126 1127.
118. Kofler H, Wambacher-Gasser B, Topar G, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1997 : 36 : 331 335.
119. Mohr C, Sunderkotter C, Hildebrand A, et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995 : 132 : 824 826.
120. Caldwell JB, Yancey KB, Engler RJ, James WD. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1994 : 31 : 827 828.
121. Meier F, Sonnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1993 : 29 : 334 337.
122. Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis. Int J Pediatr Otorhinolaryngol 2004 : 68 : 965 970.
123. Cauza K, Hinterhuber G, Sterniczky B, et al. Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. J Am Acad Dermatol 2004 : 51 (2 Suppl S112 S117.
124. Goebeler M, Seitz C, Rose C, et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol 2003 : 149 : 912 914.
125. Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 2000 : 107 : 1524 1528.
126. Kroiss MM, Vogt T, Landthaler M, Stolz W. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 2000 : 142 : 582.
127. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol 1999 : 40 : 485 488.
128. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987 : 123 : 1160 1165.
129. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing 1993 : 22 : 450 456.
130. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991 : 127 : 839 842.
131. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990 : 126 : 37 42.
132. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. The University Miami Experience Arch Dermatol 2003 : 139 : 39 43.
133. Prins C, Kerdel FA, Padilla RS, et al. TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003 : 139 : 26 32.
134. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003 : 139 : 33 36.
135. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004 : 25 : 246 255.
136. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005 : 85 : 497 502.
137. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004 : 43 : 847 851.
138. Sidwell RU, Swift S, Yan CL, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. Int J Clin Pract 2003 : 57 : 643 645.
139. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003 : 91 : 86 91.
140. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004 : 25 : 81 88.
141. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003 : 83 : 430 432.
142. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005 : 19 : 846 853.
143. Arca E, Kose O, Erbil AH, Nisanci M, Akar A, Gur AR. A 2-year-old girl with Stevens-Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin. Pediatr Dermatol 2005 : 22 : 317 320.
144. Tan A, Tan HH, Lee CC, Ng SK. Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins. Clin Exp Dermatol 2003 : 28 : 269 271.
145. Simeone F, Rubio ER. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. J State Med Soc 2003 : 155 : 266 269.
146. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003 : 112 : 1430 1436.
147. Kalyoncu M, Cimsit G, Cakir M, Okten A. Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor. Indian Pediatr 2004 : 41 : 392 395.
148. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001 : 203 : 45 49.
149. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002 : 47 : 548 552.
150. Samimi SS, Siegfried E. Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol 2002 : 19 : 52 55.
151. Brett AS, Philips D, Lynn AW. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome. South Med J 2001 : 94 : 342 343.
152. Straussberg R, Harel L, Ben-Amitai D, Cohen D, Amir J. Carbamazepine-induced Stevens-Johnson syndrome treated with IV steroids and IVIG. Pediatr Neurol 2000 : 22 : 231 233.
153. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000 : 27 : 2494 2497.
154. Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000 : 142 : 191 192.
155. Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 1999 : 40 : 153 157.
156. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996 : 98 : 1112 1115.
157. Moudgil A, Porat S, Brunnel P, Jordan SC. Treatment of Stevens-Johnson syndrome with pooled human intravenous immune globulin. Clin Pediatr (Phila) 1995 : 34 : 48 51.
158. Amato GM, Travia A, Ziino O. The use of intravenous high-dose immunoglobulins (IGIV) in a case of Stevens-Johnson syndrome. Pediatr Med Chir 1992 : 14 : 555 556.
159. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol 2004 : 50 : 286 288.
160. Jordan SC. Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. J Clin Immunol 1995 : 15 (6 Suppl 76S 85S.
161. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993 : 6 : 207 219.
162. Levy Y, Sherer Y, George J, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999 : 119 : 231 238.
163. Adlakha A, Rao K, Adlakha K, Ryu JH. A case of pediatric Wegener's granulomatosis with recurrent venous thromboses treated with intravenous immunoglobulin and laryngotracheoplasty. Pediatr Pulmonol 1995 : 20 : 265 268.
164. Tuso P, Moudgil A, Hay J, et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 1992 : 20 : 504 508.
165. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000 : 93 : 433 439.
166. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996 : 35 : 1150 1153.
167. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995 : 101 : 2 7.
168. Ito-Ihara T, Ono T, Nogaki F, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 2006 : 102 : c35 c42.
169. Bellisai F, Morozzi G, Marcolongo R, Galeazzi M. Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol 2004 : 23 : 533 535.
170. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004 : 63 : 1649 1654.
171. Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004 : 92 : 80 87.
172. Levy Y, George J, Fabbrizzi F, Rotman P, Paz Y, Shoenfeld Y. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999 : 92 : 412 414.
173. Armentia A, Fernandez A, Sanchez P, et al. Asthma and vasculitis. Response to intravenous immunoglobulins. Allergol Immunopathol (Madr) 1993 : 21 : 47 52.
174. Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 1991 : 88 : 823 824.
175. Asano Y, Ihn H, Maekawa T, Kadono T, Tamaki K. High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature. Clin Rheumatol 2006 : 25 : 396 398.
176. Kroiss M, Hohenleutner U, Gruss C, Glaessl A, Landthaler M, Stolz W. Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa. Dermatology 2001 : 203 : 188 189.
177. Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001 : 344 : 1481 1482.
178. Gedalia A, Sorensen R. Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa. Clin Exp Rheumatol 1998 : 16 : 767.
179. Uziel Y, Silverman ED. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol 1998 : 16 : 187 189.
180. Machet L, Vincent O, Machet MC, Barruet K, Vaillant L, Lorette G. Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous
181. Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994 : 343 : 1255 1258.
182. Altmeyer P, Seifarth D, Bacharach-Buhles M. High dosage intravenous immunoglobulin (IVIG) therapy in therapy-refractory ANCA-negative, necrotizing vasculitis [German]. Hautarzt 1999 : 50 : 853 858.
183. Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 2000 : 143 : 447 449.
184. Sais G, Vidaller A, Servitje O, Jucgla A, Peyri J. Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol 1996 : 98 : 232 233.
185. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 2001 : 85 : 1287 1288.
186. Greaves MW. Pathophysiology of chronic urticaria. Int Arch Allergy Immunol 2002 : 127 : 3 9.
187. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001 : 107 : 1056 1062.
188. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI. a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995 : 96 : 2606 2612.
189. Dawn G, Urcelay M, Ah-Weng A, O'Neill SM, Douglas WS. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 2003 : 149 : 836 840.
190. Darras S, Segard M, Mortier L, Bonnevalle A, Thomas P. Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy. Ann Dermatol Venereol 2004 : 131 : 65 69. [Article in French].
191. Puech-Plottova I, Michel JL, Rouchouse B, Perrot JL, Dzviga C, Cambazard F. Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol 2000 : 127 : 831 835. [Article in French].
192. Kroiss M, Vogt T, Landthaler M, Stolz W. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 2000 : 80 : 225.
193. Klote MM, Nelson MR, Engler RJ. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005 : 94 : 307 308.
194. Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000 : 55 : 1099 1101.
195. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998 : 138 : 101 106.
196. Altschul A, Cunningham-Rundles C. Chronic urticaria and angioedema as the first presentations of common variable immunodeficiency. J Allergy Clin Immunol 2002 : 110 : 664 665.
197. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998 : 138 : 101 106.
198. Orson FM. Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome. Am J Med Sci 2003 : 326 : 94 97.
199. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T-cell proliferation and cytokine production. J Immunol 1996 : 156 : 3057 3064.
200. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993 : 91 : 602 607.
201. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007 : 146 : 193 203.
202. Cone LA, Stone RA, Schlievert PM, et al. An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C. Scand J Infect Dis 2006 : 38 : 960 963.
203. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999 : 28 : 800 807.
204. Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005 : 37 : 166 172.
205. Cawley MJ, Briggs M, Haith LR Jr., et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 1999 : 19 : 1094 1098.
206. Haywood CT, McGeer A, Low DE. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 1999 : 103 : 1567 1573.
207. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude JV. Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections. case report and review. Clin Infect Dis 1995 : 21 : 1469 1470.
208. Yong JM. Necrotising fasciitis. Lancet 1994 : 343 : 1427.
209. Chapman S, Opdam H, Donato R, Johnson P. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2006 : 38 : 742 743.
210. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it. The Massachusetts General Hospital data and a review of the literature. Transfusion 2006 : 46 : 741 753.
211. Jolles S, Sewell C, Webster D, et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003 : 83 : 433 437.
212. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002 : 147 : 518 522.
213. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000 : 84 : 345 352.
214. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000 : 142 : 551 554.
215. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High-dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998 : 81 : 153 158.
216. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996 : 104 (Suppl. 1 61 66.
217. Kimata H. High-dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994 : 70 : 335 336.
218. Gurmin V, Mediwake R, Fernando M, Whittaker S, Rustin MH, Beynon HL. Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br J Dermatol 2002 : 147 : 554 557.
219. Wojas-Pelc A, Blaszczyk M, Glinska M, Jablonska S. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2005 : 19 : 462 465.
220. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 2004 : 10 : 85 86.
221. Shergill B, Orteu CH, McBride SR, Rustin MH. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 2005 : 153 : 650 652.
222. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 2004 : 29 : 317 318.
223. Kulczycki A, Nelson M, Eisen A, Heffernan M. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 2003 : 149 : 1276 1281.
224. Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002 : 61 : 59 61.
225. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000 : 43 : 403 408.
226. Antonelli A, Navarranne A, Palla R, et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 1994 : 4 : 399 408.
227. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997 : 7 : 579 585.
228. Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996 : 106 : 197 202.
229. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating nine consecutive patients. J Am Acad Dermatol 2004 : 51 : 574 579.
230. Ravat FE, Evans AV, Russell-Jones R. Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol 2002 : 147 : 166 169.
231. Schanz S, Ulmer A, Fierlbeck G. Intravenous immunoglobulin in livedo vasculitis: a new treatment option? J Am Acad Dermatol 2003 : 49 : 555 556.
232. Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000 : 18 : 404 406.
233. Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004 : 150 : 596 597.
234. Dobson CM, Parslew RA, Evans S. Superficial granulomatous pyoderma treated with intravenous immunoglobulin. J Am Acad Dermatol 2003 : 48 : 456 460.
235. Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001 : 12 : 19 22.
236. Dirschka T, Kastner U, Behrens S, Altmeyer P. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 1998 : 39 : 789 790.
237. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995 : 32 : 140 142.
238. Carmeli Y, Mevorach D, Kaminski N, Raz E. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 1994 : 73 : 2859 2861.
239. Mostella J, Pieroni R, Jones R, Finch CK. Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin. South Med J 2004 : 97 : 319 321.
240. Creamer D, McGregor JM, Hawk JL. Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy. Clin Exp Dermatol 1999 : 24 : 273 274.
241. Ahmed A. During Forum #570 "New autoimmune skin syndromes" at the 35th Annual AAD meeting; Washington, D.C. Feb 6, 2007.
242. Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol 2001 : 45 : 775 783.
243. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994 : 121 : 259 262.
244. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006 : 6 : 535 542.
245. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004 : 102 : 177 193.
246. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion. report of 4 cases and review of the literature. Arch Dermatol 2006 : 142 : 213 217.
247. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993 : 78 (6 Suppl. 2 35 40.
248. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997 : 20 : 385 393.
249. Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003 : 24 (Suppl. 4 S222 S226.
250. Lafferty TE, DeHoratius RJ, Smith JB. Aseptic meningitis as a side effect of intravenous immune gammaglobulin. J Rheumatol 1997 : 24 : 2491 2492.
251. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994 : 44 : 1180 1181.
252. Epstein JS, Zoon KC. Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. Neonatal Netw 2000 : 19 : 60 62.
253. Schwartz SL, Johnson CB. Pinocytosis as the cause of sucrose nephrosis. Nephron 1971 : 8 : 246 254.
254. Byrne NP, Henry JC, Herrmann DN, et al. Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy. Neurology 2002 : 59 : 458 461.
255. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986 : 2 : 217 218.
256. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003 : 139 : 991 993.
257. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002 : 47 : 358 363.
258. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin. Lancet 1986 : 23 : 468.
259. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997 : 13 : 775 777.
260. Ropper AH, Adelman L. Early Guillain-Barre syndrome without inflammation. Arch Neurol 1992 : 49 : 979 981.
261. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002 : 22 : 1638 1641.
262. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994 : 44 : 223 226.
263. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000 : 75 : 83 85.
264. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 2001 : 94 : 187 188.
265. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999 : 21 : 171 185.
266. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002 : 59 (12 Suppl. 6 S28 S32.
267. Hammarstrom L, Persson MA, Smith CI. Anti-IgA in selective IgA deficiency. In vitro effects and Ig subclass pattern of human anti-IgA. Scand J Immunol 1983 : 18 : 509 513.
268. Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr (Phila) 1996 : 35 : 23 31.
269. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996 : 104 (Suppl. 1 35 42.
270. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006 : 6 : 523 527.
271. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998 : 16 : 235 251.
272. Otley CC. Immunosuppression and skin cancer. pathogenetic insights, therapeutic challenges, and opportunities for innovation. Arch Dermatol 2002 : 138 : 827 828.
273. Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006 : 6 : 600 606.
274. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998 : 79 : 48 51.
275. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood 1993 : 82 : 3789.
276. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol 2004 : 43 : 163 166.
277. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998 : 112 : 341 346.
278. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004 : 114 : 936 942.
279. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006 : 26 : 177 185.